Gold tier: mechanically validated evidence, with its primary source.
150 evidence items · page 1 / 6
36 %36% of women attending large HIV care and treatment programs across Kenya between June and September 2016 knew cervical cancer is treatable.
Kenyacancer du col de l'utérusobserved June and September 2016published 2022International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument of 3 observations
24.5 %Twenty-four point five percent (23/94) of the respondents who had ever been screened perceived cervical screening procedures as embarrassing.
Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations
71 %Only 71% (27) of clinics that reported performing cervical cancer screening had dependable access to acetic acid.
Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2
44.5 %The average relative survival from cervical cancer in the 11 countries was 44.5% at 3 years.
Kenyacancer du col de l'utérusobserved 2005 to 2015published 2020International journal of cancereurope_pmcdocument of 6 observations
3.88 hazard_rate_ratioIn patients with cervical cancer, cancer-directed therapy without curative potential was associated with worse overall survival (hazard rate ratio, 3.88; 95% confidence interval, 1.19–12.71).
Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718
4 %The smallest share of guideline-adherent cancer-directed therapy was observed in Maputo (4%).
Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718
247 womenUse of the mobile phone-based app is projected to detect and treat an additional 247 women — 229 with precancerous cervical lesions and 18 with cervical cancer — in a simulated cohort of 10,000 women per arm.
Kenyacancer du col de l'utérus · precancerous cervical lesionspublished 2025PloS onePubMeddocument of 3 observations
54 %Fifty-four percent (38/70) of clinic managers reported that their clinics performed cervical cancer screening.
Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2
21,990 casesA total of 21,990 cases of cervical cancer were included in the analyses.
Kenyacancer du col de l'utéruspublished 2020British journal of cancereurope_pmcdocument of 5 observations
45.9 per_100_person_yearsOf the 162 women in the study, 70 (43.2%) died giving an overall incidence rate of 45.9 deaths per 100 person years of follow up.
Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations
70 %In Kenya, up to 70% of screen-positive women do not receive treatment.
Kenyacancer du col de l'utéruspublished 2023Implementation science : ISPubMeddocument of 2 observations
340,000 deathsGlobally, there were over 340,000 cervical cancer deaths in 2020.
Kenyacancer du col de l'utérusobserved 2020published 2023PloS onePubMeddocument of 16 observations
77.6 %The 3-year disease-free survival was 77.6% among HIV-negative patients.
Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations
Cervical cancer is currently ranked the highest cause of cancer deaths in Kenya.
Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations
In Kenya, cervical cancer is the leading cause of cancer-related mortality among women of reproductive age.
Kenyacancer du col de l'utéruspublished 2014BMC public healtheurope_pmcdocument of 2 observations
2.12 odds_ratioYoung women who did not know where to obtain condoms had an odds ratio of 2.12 for being unaware of cervical cancer.
Kenyacancer du col de l'utéruspublished 2020PloS onePubMeddocument of 5 observations
1 per_317Among 317 women, invasive cervical cancer cases included HPV16 in 1/317 (0.3%) and HPV81 in 3/317 (0.9%).
Kenyacancer du col de l'utéruspublished 2021BioMed research internationalPubMeddocument of 9 observations
60.9 %Focused training improved community health volunteers' knowledge on cervical cancer to 60.9% in the intervention arm compared to 13.4% in the control arm at end-line.
Kenyacancer du col de l'utéruspublished 2022Journal of cancer education : the official journal of the American Association for Cancer PubMeddocument of 3 observations
1.3 risk_ratioKnowing someone who had died due to cervical cancer was associated with an adjusted risk ratio of 1.30 for screening in Kenya.
Kenyacancer du col de l'utérusobserved 2022-2023published 2025BMC public healthPubMeddocument of 8 observations
84 %Negative for intraepithelial lesion or malignancy accounted for 84.0% of cervical scrape samples.
Kenyacancer du col de l'utéruspublished 2025Acta cytologicaPubMeddocument of 7 observations
Cervical cancer is the leading cause of cancer-related deaths among women in sub-Saharan Africa.
Kenyacancer du col de l'utéruspublished 2025International journal of environmental research and public healthPubMeddocument of 3 observations
94.7 %Ninety-four point seven percent (94.7%) of respondents reported that cervical cancer screening was very useful in the prevention of cervical cancer.
Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations
0.67 prevalence_ratioThe prevalence ratio for cervical cancer screening in SAIA clinics compared to control clinics was 0.67 (95% CI 0.45–1.00) in the last quarter of the trial.
Kenyacancer du col de l'utéruspublished 2023Implementation science : ISeurope_pmcdocument of 5 observationsDOI 10.1186/s13012-023-01322-y
3.1 %Worldwide cervical cancer constitutes 3.1% of all cancer cases.
Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations
42.2 %The 5-year relative survival for Stage I-II cervical cancer in low HDI registry areas was 42.2%.
Kenyacancer du col de l'utérusobserved 2005 to 2015published 2020International journal of cancereurope_pmcdocument of 6 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.